SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Morrow J. Rheumatoid arthritis autoimmune rheumatic disease. 2nd ed. Oxford: Oxford University Press; 1999. p. 10546.
  • 2
    Lee DM, Weinblatt ME. Rheumatoid arthritis. Lancet 2001; 358: 90311.
  • 3
    Kosinski M, Kujawski SC, Martin R, Wanke LA, Buatti MC, Ware JE Jr, et al. Health-related quality of life in early rheumatoid arthritis: impact of disease and treatment response. Am J Manag Care 2002; 8: 23140.
  • 4
    Suurmeijer TP, Waltz M, Moum T, Guillemin F, van Sonderen FL, Briancon S, et al. Quality of life profiles in the first years of rheumatoid arthritis: results from the EURIDISS longitudinal study. Arthritis Rheum 2001; 45: 11121.
  • 5
    Belza BL. Comparison of self-reported fatigue in rheumatoid arthritis and controls. J Rheumatol 1995; 22: 63943.
  • 6
    Wolfe F, Hawley DJ, Wilson K. The prevalence and meaning of fatigue in rheumatic disease. J Rheumatol 1996; 23: 140717.
  • 7
    Katz PP. The stresses of rheumatoid arthritis: appraisals of perceived impact and coping efficacy. Arthritis Care Res 1998; 11: 922.
  • 8
    Carr A, Hewlett S, Hughes R, Mitchell H, Ryan S, Carr M, et al. Rheumatology outcomes: the patient's perspective. J Rheumatol 2003; 30: 8803.
  • 9
    Huyser BA, Parker JC, Thoreson R, Smarr KL, Johnson JC, Hoffman R. Predictors of subjective fatigue among individuals with rheumatoid arthritis. Arthritis Rheum 1998; 41: 22307.
  • 10
    Riemsma RP, Rasker JJ, Taal E, Griep EN, Wouters JM, Wiegman O. Fatigue in rheumatoid arthritis: the role of self-efficacy and problematic social support. Br J Rheumatol 1998; 37: 10426.
  • 11
    Fifield J, McQuillan J, Tennen H, Sheehan TJ, Reisine S, Hesselbrock V, et al. History of affective disorder and the temporal trajectory of fatigue in rheumatoid arthritis. Ann Behav Med 2001; 23: 3441.
  • 12
    Belza BL, Henke CJ, Yelin EH, Epstein WV, Gilliss CL. Correlates of fatigue in older adults with rheumatoid arthritis. Nurs Res 1993; 42: 939.
  • 13
    Wolfe F. Fatigue assessments in rheumatoid arthritis: comparative performance of visual analog scales and longer fatigue questionnaires in 7760 patients. J Rheumatol 2004; 31: 1896902.
  • 14
    Goldbach-Mansky R, Lipsky PE. New concepts in the treatment of rheumatoid arthritis. Annu Rev Med 2003; 54: 197216.
  • 15
    Smolen JS, Steiner G. Therapeutic strategies for rheumatoid arthritis. Nat Rev Drug Discov 2003; 2: 47388.
  • 16
    Wolfe F, Hawley DJ, Cathey MA. Termination of slow acting antirheumatic therapy in rheumatoid arthritis: a 14-year prospective evaluation of 1017 consecutive starts. J Rheumatol 1990; 17: 9941002.
  • 17
    Aletaha D, Smolen JS. Effectiveness profiles and dose dependent retention of traditional disease modifying antirheumatic drugs for rheumatoid arthritis: an observational study. J Rheumatol 2002; 29: 16318.
  • 18
    Bathon JM, Martin RW, Fleischmann RM, Tesser JR, Schiff MH, Keystone EC, et al. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis [published errata appear in N Engl J Med 2001;344:240 and N Engl J Med 2001;344:76]. N Engl J Med 2000; 343: 158693.
  • 19
    Moreland LW, Schiff MH, Baumgartner SW, Tindall EA, Fleischmann RM, Bulpitt KJ, et al. Etanercept therapy in rheumatoid arthritis: a randomized, controlled trial. Ann Intern Med 1999; 130: 47886.
  • 20
    Weinblatt ME, Kremer JM, Bankhurst AD, Bulpitt KJ, Fleischmann RM, Fox RI, et al. A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med 1999; 340: 2539.
  • 21
    Weinblatt ME, Keystone EC, Furst DE, Moreland LW, Weisman MH, Birbara CA, et al. Adalimumab, a fully human anti–tumor necrosis factor α monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum 2003; 48: 3545.
  • 22
    Fries JF, Singh G, Ramey DR. Stanford RA, January 1996, Phase 30. Palo Alto (CA): Stanford University; 1996.
  • 23
    Beaton DE, Bombardier C, Katz JN, Wright JG, Wells G, Boers M, et al, for the OMERACT MCID Working Group. Looking for important change/differences in studies of responsiveness. J Rheumatol 2001; 28: 4005.
  • 24
    Wyrwich KW, Tierney WM, Wolinsky FD. Further evidence supporting an SEM-based criterion for identifying meaningful intra-individual changes in health-related quality of life. J Clin Epidemiol 1999; 52: 86173.
  • 25
    Felson DT, Anderson JJ, Boers M, Bombardier C, Furst D, Goldsmith C, et al. American College of Rheumatology preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 1995; 38: 72735.
  • 26
    Norman GR, Sloan JA, Wyrwich KW. Interpretation of changes in health-related quality of life: the remarkable universality of half a standard deviation. Med Care 2003; 41: 58292.
  • 27
    Singh G, Lingala B, Bennett M, Wanke L, Singh A. Fatigue in rheumatoid arthritis: significant correlation with direct medical costs and missed days of work [abstract]. Ann Rheum Dis 2003; 62 Suppl 1: 356.
  • 28
    Ruta DA, Hurst NP, Kind P, Hunter M, Stubbings A. Measuring health status in British patients with rheumatoid arthritis: reliability, validity and responsiveness of the short form 36-item health survey (SF-36). Br J Rheumatol 1998; 37: 42536.
  • 29
    Birrell FN, Hassell AB, Jones PW, Dawes PT. How does the short form 36 health questionnaire (SF-36) in rheumatoid arthritis (RA) relate to RA outcome measures and SF-36 population values? A cross-sectional study. Clin Rheumatol 2000; 19: 1959.
  • 30
    Kosinski M, Keller SD, Hatoum HT, Kong SX, Ware JE Jr. The SF-36 Health Survey as a generic outcome measure in clinical trials of patients with osteoarthritis and rheumatoid arthritis: tests of data quality, scaling assumptions and score reliability. Med Care 1999; 37 Suppl: MS1022.
  • 31
    Kosinski M, Keller SD, Ware JE Jr, Hatoum HT, Kong SX. The SF-36 Health Survey as a generic outcome measure in clinical trials of patients with osteoarthritis and rheumatoid arthritis: relative validity of scales in relation to clinical measures of arthritis severity. Med Care 1999; 37 Suppl: MS2339.
  • 32
    Singh A, Wanke LA, Parasuraman TV, Lubeck D. Reliability and validity of SF-36 vitality scale in measuring vitality of methotrexate-naive patients with early, active rheumatoid arthritis [abstract]. Arthritis Rheum 2002; 46 Suppl 9: S115.
  • 33
    Crosby RD, Kolotkin RL, Williams GR. Defining clinically meaningful change in health-related quality of life. J Clin Epidemiol 2003; 56: 395407.
  • 34
    Kosinski M, Zhao SZ, Dedhiya S, Osterhaus JT, Ware JE Jr. Determining minimally important changes in generic and disease-specific health-related quality of life questionnaires in clinical trials of rheumatoid arthritis. Arthritis Rheum 2000; 43: 147887.